CD4 and esophageal cancer: Besides, it has been reported that platinum increased intra-tumor CD4+ and CD8+ T cell trafficking in esophageal cancer.40 Carboplatin and paclitaxel have been reported to synergistically augment tumor-specific CD8+ cytotoxic responses in both mouse models and patients.41 Thus, potential combinations including T cell activating agents (TLR9, STING, and IL-10 agonists) may represent promising approaches to further augment antitumor response in GC patients.